LCZ696

Results: 5



#Item
1平野医薬ニュース 第 266 号 12/12 ２０１２．１２ Ｎ o.２６６ ◆左室駆出率の保持された心不全における アンジオテンシン受容体･ネプリライシン阻害薬 LCZ696◆

平野医薬ニュース 第 266 号 12/12 ２０１２．１２ Ｎ o.２６６ ◆左室駆出率の保持された心不全における アンジオテンシン受容体･ネプリライシン阻害薬 LCZ696◆

Add to Reading List

Source URL: www.hirano-pharmacy.co.jp

Language: Japanese - Date: 2014-01-30 23:26:44
    2Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca

    Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca

    Add to Reading List

    Source URL: www.novartis.ca

    Language: English - Date: 2015-05-13 10:22:09
    3Organic chemistry / Amides / Novartis / Carboxylic acids / Heart diseases / Valsartan / Heart failure / Enalapril / LCZ696 / Chemistry / Pharmacology / ACE inhibitors

    MEDIA STATEMENT • MEDIA STATEMENT • MEDIA STATEMENT Investigational heart failure medicine LCZ696 (sacubitril/valsartan) receives Promising Innovative Medicine designation in the UK PIM designation is the first s

    Add to Reading List

    Source URL: preview.thenewsmarket.com

    Language: English - Date: 2015-04-22 09:44:53
    4Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9

    Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9

    Add to Reading List

    Source URL: www.novartis.ca

    Language: English - Date: 2014-11-17 07:51:16
    5Long term efficacy and safety comparison of the angiotensin receptor neprilysin inhibitor (ARNi), LCZ696, and valsartan, in patients with heart failure and preserved ejection fraction: A randomized, double blind, morbidi

    Long term efficacy and safety comparison of the angiotensin receptor neprilysin inhibitor (ARNi), LCZ696, and valsartan, in patients with heart failure and preserved ejection fraction: A randomized, double blind, morbidi

    Add to Reading List

    Source URL: www.hfsa.org

    Language: English - Date: 2013-10-11 12:37:48